Position in GILD
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$1,247,860
+$449,828 QoQ
Shares Held
9,877
+72.5% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#985
of 2,266 holders
Holding Since
Sep 2020
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $7,172,969 across 8 Drug Manufacturers - General names. GILD ranks #3 (17.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMY |
Bristol Myers Squibb Co
|
28,898 | $1,665,102 | |
| 2 | LLY |
ELI LILLY & Co
|
1,075 | $1,289,387 | |
| 3 | GILD |
Gilead Sciences, Inc.
This page
|
9,877 | $1,247,860 | |
| 4 | AMGN |
Amgen Inc
|
2,641 | $956,358 | |
| 5 | GRFS |
Grifols SA
|
101,833 | $720,977 | |
| 6 | SNY |
Sanofi
|
12,660 | $540,075 | |
| 7 | NVS |
Novartis AG
|
2,762 | $432,860 | |
| 8 | MRK |
Merck & Co., Inc.
|
2,493 | $320,350 |
All Filings in GILD
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,247,860 | 9,877 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $798,032 | 5,726 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $230,137 | 1,875 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $336,885 | 3,035 | Shares | Sole | 2025-11-07 | |
| 2024-03-31 | $461,621 | 6,302 | Shares | Sole | 2024-05-03 | |
| 2023-09-30 | $270,008 | 3,603 | Shares | Sole | 2023-11-15 | |
| 2023-03-31 | $225,595 | 2,719 | Shares | Sole | 2023-05-12 | |
| 2022-03-31 | $443,972 | 7,468 | Shares | Sole | 2022-05-11 | |
| 2021-09-30 | $240,423 | 3,442 | Shares | Sole | 2021-11-12 | |
| 2021-03-31 | $474,513 | 7,342 | Shares | Sole | 2021-05-10 | |
| 2020-09-30 | $569,594 | 9,014 | Shares | Sole | 2020-11-06 | |
| No filing history on record for this holder in this stock. | ||||||